{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-276512","form_type":"8-K","ticker":null,"cik":"0001126234","company_name":"LUMOS PHARMA, INC.","filed_at":"2024-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.730132+00:00","generated_at":"2026-05-29T03:51:44.445217+00:00","sec_items":["1.02","2.01","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Lumos Pharma acquired by DPV Parent for $4.25/share plus CVR; stock delisted","bullets":["Merger completed Dec 12, 2024; shareholders received $4.25 cash plus one non-transferable CVR per share.","CVR entitles holders to milestone payments of up to $6.50 based on net revenue and company sale triggers.","Tender offer closed with 75.62% of shares tendered; merger effected under DGCL Section 251(h).","Total equity value of transaction approx $38 million; stock delisted from Nasdaq.","Entire board resigned; Christopher Uzpen appointed sole director of surviving entity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-276512","json":"https://secwatch.observer/filing/0001193125-24-276512.json","markdown":"https://secwatch.observer/filing/0001193125-24-276512.md","text":"https://secwatch.observer/filing/0001193125-24-276512.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1126234/000119312524276512/0001193125-24-276512-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1126234/000119312524276512/d909721d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:51:44.445217+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7a5e7a8cb1656c79f80edffc6c938288acae11f","claim":"LUMOS PHARMA, INC.: Certificate of incorporation amended and restated in its entirety.","evidence_excerpt":"the Surviving Corporation’s certificate of incorporation was amended and restated in its entirety, as set forth on Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1126234/000119312524276512/0001193125-24-276512-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"bfe9ff439292e8030f49db192341d04fb45d8364","claim":"LUMOS PHARMA, INC.: Bylaws of Merger Sub became bylaws of Surviving Corporation.","evidence_excerpt":"the bylaws of Merger Sub as in effect immediately prior to the Effective Time became the bylaws of the Surviving Corporation, as set forth on Exhibit 3.2 to this Current Report on Form 8-K and is incorporated herein by reference","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1126234/000119312524276512/0001193125-24-276512-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"}],"fact_type":"governance_change"},{"claim_id":"2207e1f09f4ffe81e1e345255a8f4bd631cdb0f0","claim":"LUMOS PHARMA, INC. underwent a change of control involving DPV Parent, Inc. for $4.25 per Share in cash plus one non-transferable contingent value right per Share (closed 2024-12-12).","evidence_excerpt":"2024, Merger Sub completed a tender offer to purchase all of the issued and outstanding shares of the Company’s common stock, par value $0.01 per share (the “ Shares ”), for (i) $4.25 per Share in cash, without interest and less applicable tax withholding (the “ Cash Amount ”), plus (ii) one non-transferable, unsecured contingent value right per Share, which","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1126234/000119312524276512/0001193125-24-276512-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"DPV Parent, Inc."},{"label":"Consideration","value":"$4.25 per Share in cash plus one non-transferable contingent value right per Share"},{"label":"Closing","value":"2024-12-12"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}